携带t(14;19)的慢性淋巴细胞白血病患者的临床与转录组特征:一项ERIC研究
本研究分析携带t(14;19)(q32;q13)涉及BCL3基因的慢性淋巴细胞白血病(tCLL)患者的临床与转录组特征。tCLL患者较无t(14;19)者更年轻,更常见IGHV未突变、subset #8定型、12号染色体三体及复杂核型,且至治疗时间和总生存更短。转录组显示BCL3上调、B细胞受体及PI3K-Akt通路激活、凋亡通路受抑;tCLL患者接受BTK抑制剂较维奈克拉方案有至下一治疗时间更长的趋势(p=0.058)。
要点
- tCLL患者较无t(14;19)者更年轻,更常见IGHV未突变、subset #8定型、12号染色体三体及复杂核型。
- t(14;19)与较短的至治疗时间和总生存相关。
- tCLL转录组以BCL3上调、BCR及PI3K-Akt通路激活、凋亡通路受抑为特征。
核心结论
- 研究强调tCLL的不良结局及其独特的分子特征和基因表达模式,数据提示识别tCLL可能有助于制定个体化治疗策略。
研究设计与样本
- ERIC研究,比较携带t(14;19)(q32;q13)涉及BCL3基因的CLL患者(tCLL)与无t(14;19)的CLL患者(oCLL)的临床与转录组特征。
主要发现
- tCLL患者较oCLL更年轻,更常见IGHV未突变、subset #8定型、12号染色体三体及复杂核型。
- t(14;19)与较短的至治疗时间和总生存相关。
- 基因表达分析显示tCLL中BCL3上调,B细胞受体及PI3K-Akt通路激活,凋亡相关通路受抑;BTK基因上调而编码促凋亡蛋白BIM的BCL2L11基因下调。
- tCLL患者接受BTK抑制剂较接受维奈克拉方案者有至下一治疗时间更长的趋势(p=0.058)。
临床怎么用
- 作者认为识别tCLL可能有助于制定个体化治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In chronic lymphocytic leukemia (CLL), the role of complex karyotype (CK) for prognostic stratification remains a topic of debate, and the impact of specific cytogenetic abnormalities is still unclear. This study aims to investigate the clinical and biological features of CLL with t(14;19)(q32;q13) (tCLL) involving the BCL3 gene. Patients with tCLL were younger and more commonly presented unmutated IGHV gene, subset #8 stereotypy, trisomy of chromosome 12, and complex karyotype than other patients without t(14;19) (oCLL). The presence of t(14;19) was associated with a shorter time to treatment and overall survival compared to oCLL. Gene expression analysis revealed a unique transcriptome profile in tCLL, characterized by the upregulation of BCL3 and the activation of B-cell receptor, PI3K-Akt. Conversely, apoptosis-related pathways were suppressed in tCLL. While the BTK gene was upregulated, the BCL2L11 gene, coding for the pro-apoptotic protein BIM, was downregulated. Notably, patients with tCLL were characterized by a trend (p = 0.058) for a longer time to the next treatment with BTK inhibitors (BTKi) compared to those treated with a venetoclax-based (Ven-based) regimen. We underscore the adverse outcomes of tCLL, its distinct molecular features and gene expression patterns. Therefore, our data suggest that identifying tCLL could help tailor therapeutic approaches.
引用
- Visentin A, Gaffo E, Fürstenau M, et al. Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study. Leukemia. 2025. PMID: 40973766. doi:10.1038/s41375-025-02755-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。